0001179110-21-008010.txt : 20210809 0001179110-21-008010.hdr.sgml : 20210809 20210809072116 ACCESSION NUMBER: 0001179110-21-008010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210805 FILED AS OF DATE: 20210809 DATE AS OF CHANGE: 20210809 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Marucci Anthony S CENTRAL INDEX KEY: 0001429933 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 211154622 MAIL ADDRESS: STREET 1: 66 COLD HILL DRIVE CITY: MENDAHM STATE: NJ ZIP: 07945 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 edgar.xml FORM 4 - X0306 4 2021-08-05 0 0000744218 Celldex Therapeutics, Inc. CLDX 0001429933 Marucci Anthony S C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD HAMPTON NJ 08827 1 1 0 0 President & CEO Common Stock 2021-08-05 4 M 0 3537 42.00 A 27231 D Incentive Stock Option 42.00 2021-08-05 4 M 0 3537 0.00 D 2021-08-05 Common Stock 3537 0 D Includes 4,256 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Option Plan. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. This option was previously reported as covering 180,400 shares at an exercise price of $2.80 per share, but has been adjusted to reflect the Reverse Stock Split. The remaining 8,488 shares of common stock underlying the option expired on August 5, 2021. As of August 5, 2015, the option is fully vested. /s/ Samuel B. Martin, attorney in fact for Anthony S. Marucci 2021-08-09